Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21.

Abstract

Idelalisib is a first-in-class selective oral PI3Kδ inhibitor for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma, a predominantly elderly population with high comorbidity. The drug promotes apoptosis in primary CLL cells ex vivo, independent of common prognostic markers and inhibits CLL cell homing, migration and adhesion to cells in the microenvironment. Idelalisib has shown efficacy with acceptable safety as monotherapy and combination therapy in relapsed/refractory CLL. Idelalisib has clinical activity in patients with CLL with del(17p). The development of other novel B-cell-targeted agents provides the opportunity to evaluate additional idelalisib treatment combinations for their potential to further improve outcomes in CLL/small lymphocytic lymphoma.

Keywords: B-cell receptor; PI3K; chronic lymphocytic leukemia; idelalisib; kinase inhibitor; small lymphocytic lymphoma.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials as Topic
  • Drug Interactions
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
  • Molecular Targeted Therapy
  • Phosphoinositide-3 Kinase Inhibitors
  • Purines / pharmacology
  • Purines / therapeutic use*
  • Quinazolinones / pharmacology
  • Quinazolinones / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • Purines
  • Quinazolinones
  • idelalisib